Different subtypes of breast cancers have different preferred clinical therapeutic strategies, such as anti-Estrogen therapy for Luminal A/B type, ERBB2 (Her2) target therapy for Her2/Luminal B type and chemotherapy for Basal type [19]. This evidence concerns the gene ERBB2 and breast carcinoma.